Entolimod Shown to Suppress Liver Metastases in Model of Ocular Melanoma in Collaborative Study by Cleveland BioLabs, Emory University and Roswell Park Cancer Institute
14. Dezember 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Dec 14, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI), Emory University and Roswell Park Cancer Institute (RPCI) today announced the publication of a study in...
Cleveland BioLabs Announces Expanded U.S. Patent Protection for Entolimod
30. November 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Nov 30, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance of two new patent applications by the U.S. Patent Office with claims that provide...
Cleveland BioLabs Reports Third Quarter 2015 Financial Results and Development Progress
05. November 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Nov 5, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the third quarter and nine-month period ended...
Cleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5
27. Oktober 2015 08:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Oct 27, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on November 5, 2015, it will report its financial results for the third quarter and...
Department of Defense Grants Cleveland BioLabs Second Award for Advanced Development of Entolimod as a Medical Radiation Countermeasure
21. September 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Sep 21, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP)...
Cleveland BioLabs Announces Publication of Studies Demonstrating Efficacy of Entolimod as a Radiation Countermeasure up to 48 Hours After Exposure of Nonhuman Primates to Lethal Radiation
16. September 2015 08:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Sep 16, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the publication in the scientific journal, PLOS ONE, of studies demonstrating the ability of...
Department of Defense Awards Cleveland BioLabs a $9.2 Million Contract for Advanced Development of Entolimod as a Medical Radiation Countermeasure
02. September 2015 11:48 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Sep 2, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Department of Defense (DoD) office of Congressionally Directed Medical Research...
Cleveland BioLabs to Present at Rodman & Renshaw 17th Annual Global Investment Conference
02. September 2015 08:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Sep 2, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Rodman & Renshaw 17th Annual Global Investment...
Cleveland BioLabs Announces New Patents Strengthening Entolimod Portfolio
18. August 2015 08:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Aug 18, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance or issuance of several new patents for entolimod in the U.S. and other countries,...
Cleveland BioLabs Reports Second Quarter 2015 Financial Results and Development Progress
12. August 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Aug 12, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the second quarter and for the six-month period...